Desheng Weng

Spécialisation: Clinical oncologist
Espace de travail: Chine, Canton, Sun Yat-sen University Cancer Center (SYSUCC)
Desheng Weng est spécialiste au Sun Yat-sen University Cancer Center, où il occupe les fonctions de professeur associé et de directeur adjoint du Centre de biothérapie / Oncologie médicale du mélanome et du sarcome. Ses travaux couvrent la génétique du cancer — l'étude des gènes suppresseurs de tumeurs tels que ING2, TESTIN, BATF2, LZAP et BIN1 dans le carcinome hépatocellulaire primaire et le cancer gastrique — ainsi que l'immunothérapie du cancer en tant qu'approche thérapeutique globale. Son axe de recherche clinique porte sur le mélanome et le sarcome, ainsi que sur les soins oncologiques basés sur l'immunothérapie.
Desheng Weng est spécialiste au Sun Yat-sen University Cancer Center, où il est professeur associé et directeur adjoint du Centre de biothérapie / Oncologie médicale du mélanome et du sarcome. Il combine la recherche en génétique du cancer avec des soins oncologiques axés sur l'immunothérapie. Ses recherches portent sur l'étude des gènes suppresseurs de tumeurs tels que ING2, TESTIN, BATF2, LZAP et BIN1, ainsi que sur leurs liens avec les caractéristiques cliniques du carcinome hépatocellulaire et du cancer gastrique.

Services du médecin

Dépistage génétique

Où en sommes-nous ?

1 de 3

Les détails sur ce médecin sont exhaustifs et clairs

Fortement en désaccord

Fortement d’accord

Qualifications

Desheng Weng works as a specialist at Sun Yat-sen University Cancer Center, holding the roles of Associate Professor and Deputy Director in the Biotherapy Center and Melanoma and Sarcoma Medical Oncology. His research program connects cancer genetics with immunotherapy, reflecting a biotherapy-centered approach to treating melanoma and sarcoma. In cancer genetics studies, his work includes tumor suppressor gene down-regulation and evaluating genes such as ING2, TESTIN, BATF2, LZAP, and BIN1 in primary hepatocellular carcinoma and gastric cancer. He also investigates how these tumor suppressors relate to clinicopathological parameters and explores their functional roles through in vitro assays such as proliferation, clone formation, motility, invasion, and apoptosis of tumor cell lines. Alongside genetics, Weng’s profile highlights immunotherapy as an important comprehensive method for cancer patients. For international patients, this means he participates in a program where treatment planning is informed by both tumor biology and immunotherapy concepts.

Education

Education details are not specified in the provided profile materials.

Work experience

Associate Professor and Deputy Director, Biotherapy Center / Melanoma and Sarcoma Medical Oncology, Sun Yat-sen University Cancer Center (current role).

Clinical focus and techniques

At Sun Yat-sen University Cancer Center, Desheng Weng’s clinical-research focus centers on immunotherapy and biotherapy for melanoma and sarcoma, supported by cancer genetics work.

Cancer immunotherapy as a comprehensive treatment approach.
Cancer genetics research, including tumor suppressor gene expression studies (ING2, TESTIN, BATF2, LZAP, BIN1).
Functional evaluation using in vitro proliferation, clone formation, motility, invasion, and apoptosis assays.

Professional societies and certifications

Memberships and certifications are not specified in the provided profile materials.

Academic output

Publication and citation metrics are not specified in the provided profile materials.

Courses and advanced training

Courses and advanced training are not specified in the provided profile materials.

Awards and recognition

Awards are not specified in the provided profile materials.

Desheng Weng’s role at Sun Yat-sen University Cancer Center places him within a biotherapy and immunotherapy environment for melanoma and sarcoma. The profile materials do not specify spoken languages.